"Cisplatine" redirects here. For the Brazilian province that existed from 1821 to 1828, see Cisplatina. For the conflict in that province, see Cisplatine War.
The introduction of cisplatin as a standard treatment for testicular cancer improved remission rates from 5-10% before 1974 to 75-85% by 1984.[10]
Side effects
Cisplatin has a number of side effects that can limit its use:
Nephrotoxicity (kidney damage) is the primary dose-limiting side effect and is of major clinical concern. Cisplatin selectively accumulates into the proximal tubule via basolateral-to-apical transport, where it disrupts mitochondrial energetics and endoplasmic reticulum Ca2+ homeostasis and stimulates reactive oxygen species and pro-inflammatory cytokines.[11] Multiple mitigation strategies are being explored clinically and pre-clinically, including hydration regimens, amifostine, transporter inhibitors, antioxidants, anti-inflammatories, and epoxyeicosatrienoic acids and their analogues.[11][12]
Neurotoxicity (nerve damage) can be anticipated by performing nerve conduction studies before and after treatment. Common neurological side effects of cisplatin include visual perception and hearing disorder, which can occur soon after treatment begins.[13] While triggering apoptosis through interfering with DNA replication remains the primary mechanism of cisplatin, this has not been found to contribute to neurological side effects. Recent studies have shown that cisplatin noncompetitively inhibits an archetypal, membrane-bound mechanosensitive sodium-hydrogen ion transporter known as NHE-1.[13] It is primarily found on cells of the peripheral nervous system, which are aggregated in large numbers near the ocular and aural stimuli-receiving centers. This noncompetitive interaction has been linked to hydroelectrolytic imbalances and cytoskeleton alterations, both of which have been confirmed in vitro and in vivo. However, NHE-1 inhibition has been found to be both dose-dependent (half-inhibition = 30 μg/mL) and reversible.[13] Cisplatin can increase levels of sphingosine-1-phosphate in the central nervous system, contributing to the development of post-chemotherapy cognitive impairment.[14][15]
Ototoxicity and hearing loss associated with cisplatin can be severe and is considered to be a dose-limiting side effect.[5] Audiometric analysis may be necessary to assess the severity of ototoxicity. Other drugs (such as the aminoglycoside antibiotic class) may also cause ototoxicity, and the administration of this class of antibiotics in patients receiving cisplatin is generally avoided. The ototoxicity of both the aminoglycosides and cisplatin may be related to their ability to bind to melanin in the stria vascularis of the inner ear or the generation of reactive oxygen species. In September 2022, the U.S. Food and Drug Administration (FDA) approved sodium thiosulfate under the brand name Pedmark to lessen the risk of ototoxicity and hearing loss in people receiving cisplatin.[16][17][18] There is ongoing investigation of acetylcysteine injections as a preventative measure.[5][19]
Electrolyte disturbance: Cisplatin can cause hypomagnesaemia, hypokalaemia and hypocalcaemia. The hypocalcaemia seems to occur in those with low serum magnesium secondary to cisplatin, so it is not primarily due to the cisplatin.
Hemolytic anemia can be developed after several courses of cisplatin. It is suggested that an antibody reacting with a cisplatin-red-cell membrane is responsible for hemolysis.[20]
Pharmacology
Cisplatin interferes with DNA replication, which kills the fastest proliferating cells, which in theory are cancerous. Following administration, one chloride ion is slowly displaced by water to give the aquo complexcis-[PtCl(NH3)2(H2O)]+, in a process termed aquation. Dissociation of the chloride is favored inside the cell because the intracellular chloride concentration is only 3–20% of the approximately 100 mM chloride concentration in the extracellular fluid.[21][22]
The water molecule in cis-[PtCl(NH3)2(H2O)]+ is itself easily displaced by the N-heterocyclic bases on DNA. Guanine preferentially binds. A model compound has been prepared and crystals were examined by X-ray crystallography[23]
Subsequent to formation of [PtCl(guanine-DNA)(NH3)2]+, crosslinking can occur via displacement of the other chloride, typically by another guanine.[24] Cisplatin crosslinks DNA in several different ways, interfering with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair proves impossible. In 2008, researchers were able to show that the apoptosis induced by cisplatin on human colon cancer cells depends on the mitochondrial serine-protease Omi/Htra2.[25] Since this was only demonstrated for colon carcinoma cells, it remains an open question whether the Omi/Htra2 protein participates in the cisplatin-induced apoptosis in carcinomas from other tissues.[25]
Most notable among the changes in DNA are the 1,2-intrastrand cross-links with purine bases. These include 1,2-intrastrand d(GpG) adducts, which form nearly 90% of the adducts, and the less common 1,2-intrastrand d(ApG) adducts. Coordination chemists have obtained crystals of the products of reacting cisplain with small models of DNA. Here is a POVray plot of the platinum binding to a small model of DNA.[26]
1,3-intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision repair (NER). Other adducts include inter-strand crosslinks and nonfunctional adducts that have been postulated to contribute to cisplatin's activity. Interaction with cellular proteins, particularly HMG domain proteins, has also been advanced as a mechanism of interfering with mitosis, although this is probably not its primary method of action.[27]
Cisplatin resistance
Cisplatin combination chemotherapy is the cornerstone of treatment of many cancers. Initial platinum responsiveness is high, but the majority of cancer patients will eventually relapse with cisplatin-resistant disease. Many mechanisms of cisplatin resistance have been proposed, including changes in cellular uptake and efflux of the drug, increased detoxification of the drug, inhibition of apoptosis , increased DNA repair or changes in metabolism.[28][29]Oxaliplatin is active in highly cisplatin-resistant cancer cells in the laboratory; however, there is little evidence for its activity in the clinical treatment of patients with cisplatin-resistant cancer.[29] The drug paclitaxel may be useful in the treatment of cisplatin-resistant cancer; the mechanism for this activity is as yet unknown.[30]
Transplatin
Transplatin, the trans-stereoisomer of cisplatin, has formula trans-[PtCl2(NH3)2] and does not exhibit a comparably useful pharmacological effect. Two mechanisms have been suggested to explain the reduced anticancer effect of transplatin. Firstly, the trans arrangement of the chloro ligands is thought to confer transplatin with greater chemical reactivity, causing transplatin to become deactivated before it reaches the DNA, where cisplatin exerts its pharmacological action. Secondly, the stereo-conformation of transplatin is such that it is unable to form the characteristic 1,2-intrastrand d(GpG) adducts formed by cisplatin in abundance.[31]
Molecular structure
Cisplatin is the square planarcoordination complex cis-[Pt(NH3)2Cl2].[32]: 286–8 [33]: 689 The prefix cis indicates the cis isomer in which two similar ligands are in adjacent positions.[32][33]: 550 The systematic chemical name of this molecule is cis–diamminedichloroplatinum,[32]: 286 where ammine with two m's indicates an ammonia (NH3) ligand, as opposed to an organic amine with one m.[32]: 284
Solution structure of cisplatin (highlighted) interstrand GG adducts with double-stranded DNA. (PDB: 1DDP)
2.60Å resolution crystal structure of cisplatin (highlighted) intrastrand GG adducts with double-stranded DNA. Note: the hydrogens on amine ligands are not shown. (PDB: 1AIO)
History
The compound cis-[Pt(NH3)2Cl2] was first described by Italian chemist Michele Peyrone in 1845, and known for a long time as Peyrone's salt.[34][35] The structure was deduced by Alfred Werner in 1893.[24] In 1965, Barnett Rosenberg, Van Camp et al. of Michigan State University discovered that electrolysis of platinum electrodes generated a soluble platinum complex which inhibited binary fission in Escherichia coli (E. coli) bacteria. Although bacterial cell growth continued, cell division was arrested, the bacteria growing as filaments up to 300 times their normal length.[36] The octahedral Pt(IV) complex cis-[PtCl4(NH3)2], but not the trans isomer, was found to be effective at forcing filamentous growth of E. coli cells. The square planar Pt(II) complex, cis-[PtCl2(NH3)2] turned out to be even more effective at forcing filamentous growth.[37][38] This finding led to the observation that cis-[PtCl2(NH3)2] was indeed highly effective at regressing the mass of sarcomas in rats.[39] Confirmation of this discovery, and extension of testing to other tumour cell lines launched the medicinal applications of cisplatin. Cisplatin was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration on 19 December 1978.[24][40][41] and in the UK (and in several other European countries) in 1979.[42]
Cisplatin was the first to be developed.[43]
In 1983 pediatric oncologist Roger Packer began incorporating cisplatin into adjuvant chemotherapy for the treatment of childhood medulloblastoma.[44] The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, up to around 85%.[45] The Packer Protocol has since become a standard treatment for medulloblastoma. Likewise, cisplatin has been found to be particularly effective against testicular cancer, where its use improved the cure rate from 10% to 85%.[10]
Recently, some researchers have investigated at the preclinical level new forms of cisplatin prodrugs in combination with nanomaterials in order to localize the release of the drug in the target.[46][47]
Synthesis
Syntheses of cisplatin start from potassium tetrachloroplatinate. Several procedures are available. One obstacle is the facile formation of Magnus's green salt (MGS), which has the same empirical formula as cisplatin. The traditional way to avoid MGS involves the conversion of K2PtCl4 to K2PtI4, as originally described by Dhara.[48][49] Reaction with ammonia forms PtI2(NH3)2 which is isolated as a yellow compound. When silver nitrate in water is added insoluble silver iodide precipitates and [Pt(OH2)2(NH3)2](NO3)2 remains in solution. Addition of potassium chloride will form the final product which precipitates[49] In the triiodo intermediate the addition of the second ammonia ligand is governed by the trans effect.[49]
A one-pot synthesis of cisplatin from K2PtCl4 has been developed. It relies on the slow release of ammonia from ammonium acetate.[50]
Research
Cisplatin has been studied with Auger therapy to increase the therapeutic effects of cisplatin, without increasing normal tissue toxicities.[51] However, due to significant side effects, the search for structurally novel Pt(II) and Pd(II) compounds exhibiting antineoplastic activity is extremely important and aims to develop more effective and less toxic drugs.[52] Metal complexes comprising cisplatin-like molecules ([PtCl(NH3)2] or [Pt(NH3)Cl2]) linked by variable length alkandiamine chains have attracted great interest in the last few years as next-generation alternatives drugs in cancer chemotherapy.[53][54][55]
^ abcdefghi"Cisplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
^Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID29632935.
^World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^ abEinhorn LH (November 1990). "Treatment of testicular cancer: a new and improved model". Journal of Clinical Oncology. 8 (11): 1777–81. doi:10.1200/JCO.1990.8.11.1777. PMID1700077.
^Sarafraz Z, Ahmadi A, Daneshi A (June 2018). "Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial". The International Tinnitus Journal. 22 (1): 40–45. doi:10.5935/0946-5448.20180007. PMID29993216.
^Orbell JD, Solorzano C, Marzilli LG, Kistenmacher TJ (October 1982). "Preparation and structure of cis-chlorodiammine (N2, N2-dimethyl-9-methylguanine) platinum (II) hexafluorophosphate. A model for the intermediate in the proposed crosslinking mode of action of platinum (II) antitumor agents". Inorganic Chemistry. 21 (10): 3806–3810. doi:10.1021/ic00140a041.
^ abPruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J (June 2008). "Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells". Journal of Chemotherapy. 20 (3): 348–354. doi:10.1179/joc.2008.20.3.348. PMID18606591. S2CID11052459.
^Sherman SE, Gibson D, Wang AH, Lippard SJ (October 1985). "X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]". Science. 230 (4724): 412–7. Bibcode:1985Sci...230..412S. doi:10.1126/science.4048939. PMID4048939.
^Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, et al. (May 2019). "Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition". Free Radical Biology & Medicine. 135: 167–181. doi:10.1016/j.freeradbiomed.2019.03.009. hdl:10486/688357. PMID30880247.
^Coluccia M, Natile G (January 2007). "Trans-platinum complexes in cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 7 (1): 111–123. doi:10.2174/187152007779314080. PMID17266508.
^Kauffman GB, Pentimalli R, Hall MD (2010). "Michele Peyrone (1813–1883), Discoverer of Cisplatin". Platinum Metals Review. 54 (4): 250–256. doi:10.1595/147106710X534326. Retrieved 3 October 2022. This biographical article aims to present, for the first time in the English language, a summary of his life and the achievements that he made during his scientific career.
^Christie DA, Tansey EM (2007). Christie DA, Tansey EM, Thomson AJ (eds.). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agent for Cancer. Wellcome Trust Witnesses to Twentieth Century Medicine. Vol. 30. pp. 6–15. ISBN978-0-85484-112-7.
^Carpenter DP (2010). Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton, NJ: Princeton University Press. ISBN978-0-691-14180-0.
^Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. (November 1994). "Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy". Journal of Neurosurgery. 81 (5): 690–8. doi:10.3171/jns.1994.81.5.0690. PMID7931615.
^Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. (March 1991). "Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma". Journal of Neurosurgery. 74 (3): 433–40. doi:10.3171/jns.1991.74.3.0433. PMID1847194.
^Kukushikin VY, Oskarsson Å, Elding LI, Farrell N (2007). "Facile Synthesis of Isomerically Pure cis -Dichlorodiammineplatinum(II), Cisplatin". Facile Synthesis of Isomerically Pure cis -Dichlorodiammineplatinum(II), Cisplatin. Inorganic Syntheses. Vol. 32. pp. 141–144. doi:10.1002/9780470132630.ch23. ISBN9780470132630.
^Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, et al. (May 2004). "Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates". Journal of Medicinal Chemistry. 47 (11): 2917–2925. doi:10.1021/jm0311238. hdl:10316/10605. PMID15139770.
^Omondi RO, Ojwach SO, Jaganyi D (November 2020). "Review of comparative studies of cytotoxic activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) complexes, their kinetics of ligand substitution reactions and DNA/BSA interactions". Inorganica Chimica Acta. 512: 119883. doi:10.1016/j.ica.2020.119883. S2CID225575546.
Riddell IA, Lippard SJ (2018). "Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions". In Sigel A, Sigel H, Freisinger E, Sigel RK (eds.). Metallo-Drugs: Development and Action of Anticancer Agents. Metal Ions in Life Sciences. Vol. 18. Berlin: de Gruyter GmbH. pp. 1–42. doi:10.1515/9783110470734-007. ISBN978-3-11-046984-4. PMID29394020.
External links
"Cisplatin". Drug Information Portal. U.S. National Library of Medicine.
Airport in Shizuoka, JapanHamamatsu Air Base浜松基地Hamamatsu-kichiIATA: noneICAO: RJNHSummaryAirport typeMilitaryOwnerMinistry of DefenseOperatorJASDFLocationHamamatsu, Shizuoka, JapanElevation AMSL150 ft / 46 mCoordinates34°45′01″N 137°42′11″E / 34.75028°N 137.70306°E / 34.75028; 137.70306MapRJNHLocation in JapanShow map of Shizuoka PrefectureRJNHRJNH (Japan)Show map of JapanRunways Direction Length Surface m ft 09/27 2,550 8,366 Concrete …
Questa voce sull'argomento singoli pop è solo un abbozzo. Contribuisci a migliorarla secondo le convenzioni di Wikipedia. Segui i suggerimenti del progetto di riferimento. Morirò d'amoresingolo discograficoScreenshot tratto dal video del branoArtistaJovanotti Pubblicazione17 maggio 2002 Durata4:13 Album di provenienzaLorenzo 2002 - Il quinto mondo GenerePop EtichettaMercury, Universal Music ProduttoreJovanotti e Carlo Ubaldo Rossi Registrazione2002 Jovanotti - cronologiaSingolo precedente…
Municipality in Catalonia, SpainAlcanarMunicipalityAlcanar's harbour FlagCoat of armsAlcanarLocation of AlcanarShow map of Province of TarragonaAlcanarAlcanar (Catalonia)Show map of CataloniaAlcanarAlcanar (Spain)Show map of SpainCoordinates: 40°32′38″N 0°28′55″E / 40.544°N 0.482°E / 40.544; 0.482Country SpainAutonomous community CataloniaProvinceTarragonaComarcaMontsiàGovernment • MayorAlfons Montserrat Esteller (2015)[1] (ERC)A…
For military history, see Military history of Nova Scotia. Part of a series on theHistory of Nova ScotiaBluenose Events Port Royal established 1605 Conquest of Acadia 1710 Halifax established 1749 Bay of Fundy Campaign 1755 Fall of Louisbourg 1758 Representative Government established 1758 Halifax Treaties 1760–61 First significant Scottish immigration 1773 Battle of Fort Cumberland 1776 Birchtown established 1783 Capture of USS Chesapeake 1813 Freedom of the Press 1835 First Acadian MLA elect…
Cet article possède un paronyme, voir Acidcloridrix. Cet article concerne le chlorure d’hydrogène en solution. Pour le gaz, voir Chlorure d'hydrogène. Pour les articles homonymes, voir HCL. Acide chlorhydrique Ion hydronium et chlorure constituant l'acide chlorhydrique. Identification Nom UICPA acide chlorhydrique Synonymes solution de chlorure d'hydrogène, autrefois acide muriatique, esprit de sel No CAS 7647-01-0 No ECHA 100.210.665 No CE 231-595-7 No RTECS MW4025000 Code ATC B05XA13…
Village in Warmian-Masurian Voivodeship, PolandNawiadyVillageNawiadyCoordinates: 53°43′N 21°19′E / 53.717°N 21.317°E / 53.717; 21.317Country PolandVoivodeshipWarmian-MasurianCountyMrągowoGminaPiecki Nawiady [naˈvjadɨ] is a village in the administrative district of Gmina Piecki, within Mrągowo County, Warmian-Masurian Voivodeship, in northern Poland.[1] It lies approximately 4 kilometres (2 mi) south-west of Piecki, 17 km (11 mi) sou…
Association football club in England Football clubHanworth VillaFull nameHanworth Villa Football ClubNickname(s)The VillainsFounded1976GroundRectory Meadow, HanworthCapacity1,000 (100 seated)[1]ChairmanJames ConnorManagerSimon HaughneyLeagueIsthmian League South Central Division2023–24Isthmian League South Central Division, 7th of 21 Home colours Away colours Hanworth Villa Football Club is a football club based in Hanworth, London Borough of Hounslow, England. They are currently membe…
تعتمد هذه المقالة اعتماداً كاملاً أو شبه كامل على مصدر وحيد. فضلاً، ساهم في تحسين هذه المقالة بإضافة مصادر إضافية لضمان وجهة النظر المحايدة. (ديسمبر 2018) قبة الملك العادل طومان باي بالقاهرة الملك العادل طومان باي المماليك البرجية الخامس والعشرين في المنصب 1501 – 906هـ/…
1927–28 cabinet of Weimar Germany Fourth Cabinet of Wilhelm Marx15th Cabinet of Weimar Germany29 January 1927 – 12 June 1928(until 28 June 1928 as caretaker government)Members of the cabinetDate formed29 January 1927 (1927-01-29)Date dissolved28 June 1928 (1928-06-28)(1 year, 4 months and 30 days)People and organisationsPresidentPaul von HindenburgChancellorWilhelm MarxVice ChancellorOskar HergtMember partiesCentre PartyGerman People's PartyBavari…
Bush TheatreUbicazioneStato Regno Unito LocalitàLondra IndirizzoShepherd's Bush Dati tecniciCapienza180 posti RealizzazioneCostruzioneXX secolo Inaugurazione6 aprile 1972 ProprietarioAlternative Theatre Company Sito ufficiale Modifica dati su Wikidata · Manuale Il Bush Theatre è un teatro londinese sito nel quartiere di Hammersmith e Fulham. Il teatro fu fondato nel 1972 ed è specializzato nella messa in scena di opere di drammaturghi contemporanei ed emergenti. Indice 1 Storia 2 D…
Further education college in Darlington, County Durham, EnglandDarlington CollegeAddressCentral ParkHaughton RoadDarlington, County Durham, DL1 1DREnglandInformationTypeFurther education collegeDepartment for Education URN130656 TablesOfstedReportsPrincipalDavid GartlandAge14+Telephone01325 503050Fax01325 503000Websitehttp://www.darlington.ac.uk Darlington College Exterior Darlington College Central Point Darlington College is a further education college in Darlington, County Durham, England. Th…
For assistance with IPA transcriptions of Czech for Wikipedia articles, see Help:IPA/Czech. This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (November 2015) (Learn how and when to remove this message) This article contains phonetic transcriptions in the International Phonetic Alphabet (IPA). For an introductory guide on IPA symbols, see Help:IPA. For the d…
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: Adamstown railway station Ireland – news · newspapers · books · scholar · JSTOR (November 2015) AdamstownBaile AdaimAdamstown's station building, as seen from platforms 2 and 4.General informationLocationStation Road, Adamstown Castle, Lucan, County…
District of Nottinghamshire, England Non-metropolitan district in EnglandBassetlaw DistrictNon-metropolitan districtFrom left to right:Top: The Dunham Bridge in Dunham on Trent connecting Lincolnshire and Nottinghamshire and also a toll bridgeMiddle 1st: Harworth Bircotes and Tuxford town centresMiddle 2nd: Blyth Priory Church and Worksop Priory churchLower: Retford Town HallShown within NottinghamshireSovereign stateUnited KingdomConstituent countryEnglandRegionEast MidlandsAdministrative count…
دوري بوروندي الممتاز 2017–18 تفاصيل الموسم دوري بوروندي الممتاز البلد بوروندي البطل نادي لو ميساجير نجوزي مباريات ملعوبة 240 عدد المشاركين 16 دوري بوروندي الممتاز 2016–17 دوري بوروندي الممتاز 2018–19 تعديل مصدري - تعديل دوري بوروندي الممتاز 2017–18 هو موسم …
Cocumontcomune Cocumont – Veduta LocalizzazioneStato Francia Regione Nuova Aquitania Dipartimento Lot e Garonna ArrondissementMarmande CantoneMarmande-1 TerritorioCoordinate44°27′N 0°02′E44°27′N, 0°02′E (Cocumont) Altitudine135 m s.l.m. Superficie25,32 km² Abitanti987[1] (2009) Densità38,98 ab./km² Altre informazioniCod. postale47250 Fuso orarioUTC+1 Codice INSEE47068 CartografiaCocumont Sito istituzionaleModifica dati su Wikidata · Ma…